Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.
News Medical on MSN1h
Machine learning tool predicts cancer treatment response based on genetic mutationsA groundbreaking study led by USC Assistant Professor of Computer Science Ruishan Liu has uncovered how specific genetic mutations influence cancer treatment outcomes-insights that could help doctors ...
AI creates anti-cancer molecules for proteins that previously could not be targeted pharmacologically by leveraging quantum ...
Rising air pollution, changes in hormone levels, immune system imbalances and longer life expectancy are increasing the risk ...
A groundbreaking study led by USC Assistant Professor of Computer Science Ruishan Liu has uncovered how specific genetic ...
Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...
Panel A summarizes the conventional model of how oncogenic RAS guanosine triphosphatases (i.e., Kirsten rat sarcoma viral oncogene homologue [KRAS], neuroblastoma RAS viral oncogene homologue ...
Quantum computing and artificial intelligence (AI) can be combined with classical computing methods to design and discover ...
Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...
Incyte has a strong track record of revenue growth and a robust pipeline, targeting over 10 high-impact product launches by ...
Alexander I. Spira, MD, PhD, FACP, discusses the next steps in the clinical development of zoldonrasib for patients with KRAS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback